New! View global litigation for patent families

US20120059063A1 - Combinations of adapalene and benzoyl peroxide for treating acne lesions - Google Patents

Combinations of adapalene and benzoyl peroxide for treating acne lesions Download PDF

Info

Publication number
US20120059063A1
US20120059063A1 US13296186 US201113296186A US2012059063A1 US 20120059063 A1 US20120059063 A1 US 20120059063A1 US 13296186 US13296186 US 13296186 US 201113296186 A US201113296186 A US 201113296186A US 2012059063 A1 US2012059063 A1 US 2012059063A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
adapalene
bpo
composition
lesions
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US13296186
Inventor
Marie-line Abou-Chacra Vernet
Denis Gross
Christian Loesche
Michel Poncet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma R&D SNC
Original Assignee
Galderma R&D SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/327Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-arylpropionic acids, ethacrynic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/857Dermatitis
    • Y10S514/859Acne

Abstract

Adapalene or a pharmaceutically acceptable salt thereof formulated into a pharmaceutical composition is useful for reducing the number of acne lesions, via daily topical application, in combination or in association with benzoyl peroxide (BPO); such treatment may be via administration of a pharmaceutical composition combining adapalene and BPO or by a concomitant application of two pharmaceutical compositions, one containing adapalene and the other containing BPO.

Description

    CROSS-REFERENCE TO EARLIER APPLICATIONS
  • [0001]
    This application is a continuation of U.S. application Ser. No. 12/318,937, filed Jan. 13, 2009, now allowed, which is a continuation of PCT/EP 2007/057207, filed Jul. 12, 2007 and designating the United States (published in the English language on January 17, 2008 as WO 2008/006888 A1); which claims priority under 35 U.S.C. §119 of FR 0652968, filed Jul. 13, 2006 and claims benefit of U.S. Provisional Application No. 60/833,491, filed Jul. 27, 2006; each earlier application hereby expressly incorporated by reference in its entirety and each assigned to the assignee hereof.
  • BACKGROUND OF THE INVENTION
  • [0002]
    1. Technical Field of the Invention
  • [0003]
    The present invention relates to the combined or associated administration of adapalene and of benzoyl peroxide for reducing the number of acne lesions.
  • [0004]
    6-[3-(1-Adamantyl)-4-methoxyphenyl]-2-naphthoic acid (referred to hereinbelow as adapalene) is a naphthoic acid derivative with retinoid and anti-inflammatory properties. This molecule was developed for the topical treatment of common acne and of dermatoses sensitive to retinoids.
  • [0005]
    2. Description of Background and/or Related and/or Prior Art
  • [0006]
    Adapalene is marketed under the trademark Differin® at a weight concentration of 0.1%, in the form of an “alcoholic lotion” solution, an aqueous gel and a cream. These compositions are useful for treating acne. FR 2,837,101 describes adapalene compositions at a weight concentration of 0.3%, for treating acne.
  • [0007]
    WO 03/055 472 moreover describes stable pharmaceutical compositions comprising adapalene and benzoyl peroxide (BPO).
  • [0008]
    An article by Korkut and Piskin, J. Dermatology, 2005, 32: 169-173, reports the results of a study comparing a treatment combining application of adapalene in the evening and application of BPO in the morning, relative to an application of each of the active principles alone. The authors do not observe any superiority of the combined treatment over a period of 11 weeks of treatment.
  • SUMMARY OF THE INVENTION
  • [0009]
    It has now been demonstrated, surprisingly, that a therapeutic association or combination of adapalene and BPO can provide a degree of success in reducing the number of acne lesions and an improvement in the clinical condition of patients that are markedly superior to those of a treatment based on adapalene alone or on BPO alone, while at the same time maintaining the same skin tolerance.
  • [0010]
    The recommended treatment may take the form of a pharmaceutical composition combining adapalene and BPO, or a concomitant application of two pharmaceutical compositions, one comprising adapalene and the other comprising BPO.
  • [0011]
    The present invention thus features formulation of adapalene or a pharmaceutically acceptable salt thereof into a pharmaceutical composition, especially at set doses, intended to be administered in combination or in association with benzoyl peroxide (BPO), for the treatment of acne lesions, especially to reduce the number of acne lesions and to improve the clinical condition of patients.
  • [0012]
    Preferably, the acne lesions are of inflammatory and/or non-inflammatory type.
  • [0013]
    Acne is initially characterized by keratinization disorders, which are sometimes invisible to the naked eye. Visible acne lesions then develop, while the size of the sebaceous glands and the production of sebum increase.
  • [0014]
    The present invention specifically concerns acne lesions. The term “acne lesions” means non-inflammatory lesions (open and closed comedones) and inflammatory lesions (papules, pustules, nodules and cysts) caused by acne. Preferably, the inflammatory lesions are treated with the association or the combination according to the invention.
  • [0015]
    More preferably, the pharmaceutical composition is administered by daily cutaneous topical application. In other words, the invention relates to the administration of adapalene as an agent for potentiating the action of BPO. Reciprocally, BPO potentiates the action of adapalene.
  • [0016]
    The term “adapalene salts” means the salts formed with a pharmaceutically acceptable base, especially mineral bases such as sodium hydroxide, potassium hydroxide and ammonia or organic bases such as lysine, arginine or N-methylglucamine. The term “adapalene salts” also means the salts formed with fatty amines such as dioctylamine and stearylamine.
  • [0017]
    The expression “combination of adapalene or salts thereof with benzoyl peroxide” means a single composition comprising both adapalene or salts thereof and benzoyl peroxide.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • [0018]
    FIGS. 1-3 are graphs showing the change in the number of lesions over time, upon treatment either according to the invention or not;
  • [0019]
    FIG. 4 is a graph showing the degree of success over time of treatment according to the invention or not; and
  • [0020]
    FIG. 5 is a bar graph evaluating the anti-inflammatory effect on ear edema of treatment according to the invention or not.
  • DETAILED DESCRIPTION OF BEST MODE AND SPECIFIC/PREFERRED EMBODIMENTS OF THE INVENTION
  • [0021]
    According to one preferred embodiment, the pharmaceutical composition is a fixed combination and comprises, in a pharmaceutically acceptable medium, (i) at least one compound selected from among adapalene and pharmaceutically acceptable salts thereof, and (ii) benzoyl peroxide (BPO). Preferably, the pharmaceutical composition is intended for a single topical application per day.
  • [0022]
    The term “pharmaceutically acceptable medium” means a medium that is compatible with the skin, mucous membranes and the integuments.
  • [0023]
    The term “fixed combination” should be understood as meaning a combination whose active principles are combined at fixed doses in the same vehicle (single formula) that delivers them together to the point of application. Preferably, the pharmaceutical composition in the form of a fixed combination is a gel; in this case, the two active principles are dispersed and intimately mixed, during production, in the same vehicle, which delivers them together during the application of the gel.
  • [0024]
    In another embodiment of the invention, the pharmaceutical composition is in the form of a composition A comprising adapalene, suited to be applied concomitantly with a composition B comprising BPO. Preferably, composition A and composition B are presented in the form of a kit, preferably comprising two isolated compartments each containing one of the two pharmaceutical compositions A or B (dual pack) and allowing simultaneous administration of the two compositions, or alternatively in the form of a kit combining in the same presentation at least the two products (compositions A and B) in two separate packages, preferably in the form of tubes (co-packaging).
  • [0025]
    In this case, one skilled in this art will adapt the formula that is the most appropriate in terms of viscosity, additives, etc. to the selected kit.
  • [0026]
    The expression “concomitant” application means that the compositions are suited to be applied to the skin simultaneously or one after the other, in any order, or in a sequential order (for example, in which the application of a pharmaceutical composition B comprising BPO precedes the application of the pharmaceutical composition A comprising adapalene), but within a time interval of less than 1 hour, preferably less than 30 minutes, preferably less than 15 minutes, more preferably less than 5 minutes or even less than 1 minute.
  • [0027]
    The present invention thus also features compositions in kit form comprising at least two components:
  • [0028]
    a first component comprising at least adapalene or a pharmaceutically acceptable salt thereof,
  • [0029]
    a second component comprising benzoyl peroxide, these two components being suited to be applied concomitantly to the skin, mucous membranes and/or the integuments.
  • [0030]
    Compositions A and B are preferably useful for a single cutaneous topical application per day.
  • [0031]
    The treatments have a variable duration, depending on the patient and the severity of his acne. The treatment period may thus run from several weeks to several months. A suitable treatment period is at least two weeks, preferably from 1 to 6 months and more preferably a duration of about 3 months is preferable, the duration of the treatment possibly being prolonged, if necessary.
  • [0032]
    All the pharmaceutical compositions of the invention may comprise from 0.01% to 2%, preferably from 0.05% to 0.5% and preferentially from 0.1% to 0.3% of adapalene, and from 0.1% to 20% and preferably from 0.5% to 10% of BPO, more preferably from 2% to 5% of BPO and preferentially 2.5% of BPO.
  • [0033]
    All the percentages are indicated by weight relative to the total weight of the composition.
  • [0034]
    The adapalene:BPO ratio ranges from 1:1 to 1:200 and, conversely, the BPO:adapalene ratio ranges from 1:1 to 1:200. Preferably, the adapalene:BPO ratio ranges from 1:1 to 1:200 and the adapalene:BPO ratio is preferably 1:25.
  • [0035]
    Preferably, the effect of the combination of the two active principles is at least an additive effect and preferentially a potentiation or synergistic effect. The terms “potentiation effect” and “synergistic effect” mean a therapeutic effect (degree of success) greater than the effect resulting from the addition of the effects obtained by each of the two active principles taken separately.
  • [0036]
    When they are combined in the same pharmaceutical composition, the adapalene and the BPO are present in the pharmaceutical composition in synergistic amounts, i.e., such that a synergistic or potentiation effect on the acne lesions and on the clinical condition of the patient is observed. Preferably, the pharmaceutical composition comprises 0.1% of adapalene and 2.5% of BPO.
  • [0037]
    When compositions A and B are administered separately, the adapalene and the BPO are, respectively, present in composition A and composition B in synergistic amounts, i.e., such that a synergistic or potentiation effect on the acne lesions and on the clinical condition of the patient is observed, especially when the compositions are applied in association in equal amounts. Preferably, composition A comprises 0.1% of adapalene and composition B comprises 2.5% of BPO.
  • [0038]
    In this regard, the examples to follow demonstrate that because of the synergistic effect of adapalene and BPO, the invention provides greater efficacy for the treatment of acne in general and of acne lesions in particular and a quicker onset of action relative to monotherapies.
  • [0039]
    The pharmaceutical compositions according to the invention may be in the form of ointments, emulsions preferably in the form of creams, milks or pomades; powders, impregnated pads, solutions, gels, sprays, lotions or suspensions. They may also be in the form of suspensions of microspheres or nanospheres or of lipid or polymer vesicles or of polymer patches and/or of hydrogels allowing controlled release. These compositions may be in anhydrous form, in aqueous form or in the form of an emulsion.
  • [0040]
    In one preferred embodiment of the invention, the pharmaceutical compositions are in the form of a gel, a cream or a solution referred to as a lotion.
  • [0041]
    Preferably, the pharmaceutical compositions combining adapalene and BPO, or the pharmaceutical compositions A and/or B, are gels.
  • [0042]
    The pharmaceutical compositions of the invention may contain inert additives or combinations of these additives, such as:
  • [0043]
    wetting agents;
  • [0044]
    texture enhancers;
  • [0045]
    preservatives such as para-hydroxybenzoic acid esters;
  • [0046]
    stabilizers;
  • [0047]
    humidity regulators;
  • [0048]
    pH regulators;
  • [0049]
    osmotic pressure modifiers;
  • [0050]
    emulsifiers;
  • [0051]
    UV-A and UV-B screening agents; and
  • [0052]
    antioxidants, such as a-tocopherol, butylhydroxyanisole or butylhydroxytoluene, superoxide dismutase, ubiquinol, or certain metal-chelating agents.
  • [0053]
    Needless to say, one skilled in this art will take care to select the optional compound(s) to be added to these compositions such that the advantageous properties intrinsically associated with the present invention are not, or are not substantially, adversely affected by the envisaged addition.
  • [0054]
    According to one particular embodiment, the pharmaceutical composition A comprising adapalene may be an aqueous gel especially containing one or more ingredients selected from among the carbomer 940 (BF Goodrich Carbopol 980) and propylene glycol, or a cream especially containing one or more ingredients selected from among perhydrosqualene, cyclomethicone, PEG-20 methylglucose sesquistearate and methylglucose sesquistearate or an “alcoholic lotion” solution based on polyethylene glycol.
  • [0055]
    Useful pharmaceutical compositions, comprising adapalene and BPO, are moreover described in WO 03/055 472. Examples of such compositions comprise, besides the active principles adapalene and BPO:
  • [0056]
    from 5% to 25% of water;
  • [0057]
    from 0 to 10%, preferably from 0 to 2% and preferably less than 0.5% of liquid wetting surfactant;
  • [0058]
    from 0 to 10% of pro-penetrating agent; and
  • [0059]
    an aqueous phase comprising a pH-independent gelling agent.
  • [0060]
    According to one preferred embodiment, the preferred pharmaceutical composition, comprising adapalene and BPO, is an aqueous gel having the following formulation:
  • [0061]
    2.5% of BPO;
  • [0062]
    0.1% of adapalene;
  • [0063]
    0.10% of disodium EDTA;
  • [0064]
    4.00% of glycerol;
  • [0065]
    4.00% of propylene glycol; and also, preferably:
  • [0066]
    0.05% of sodium docusate;
  • [0067]
    0.20% of poloxamer 124;
  • [0068]
    4.00% of sodium acryloyldimethyltaurate copolymer and isohexadecane and polysorbate 80;
  • [0069]
    NaOH, in an amount sufficient to obtain a pH of 5.
  • [0070]
    The acne targeted comprises all forms of acne, including common acne, comedones, polymorphs, nodulocystic acne, acne conglobata, and secondary acne such as solar, medicational or occupational acne. The acne may in particular be of mild to severe intensity and preferably of mild to moderate intensity. The compositions according to the invention may be administered as a firstline treatment, and also after failure of other specific treatments including the administration of adapalene and/or of BPO according to the conditions described by Korkut et al.
  • [0071]
    The association or combination of adapalene and of BPO makes it possible to reduce not only the number of inflammatory acne lesions but also the non-inflammatory acne lesions and to observe an improvement in the patient's clinical condition. A potentiation or synergistic effect is observed. This potentiation effect described in the example to follow is shown in the reduced number of lesions and in the percentage of cured patients (clear) and almost cured patients (almost clear) by the size of the superiority of the combination at fixed doses of adapalene and of BPO, relative to the active substances taken individually at the same doses as the combination.
  • [0072]
    Moreover, the results of the potentiation effect of the combination of adapalene and BPO presented in the example are statistically different from the results obtained for the active substances taken individually.
  • [0073]
    The combination or association of adapalene and of BPO is thus particularly useful for reducing the number of inflammatory and/or non-inflammatory acne lesions. Preferably, the reduction is at least about 40%, preferably at least about 50% and more preferably the reduction is at least about 60%. Similarly, it is demonstrated in the example that the reduction of the total lesions is from about 35% to 80% and preferably from about 50% to 70%.
  • [0074]
    According to another embodiment, this invention also features a pharmaceutical assembly (product) comprising:
  • [0075]
    i) a container delimiting at least one compartment, the said container being closed by means of a closing member; and
  • [0076]
    ii) a pharmaceutical composition comprising adapalene or a pharmaceutically acceptable salt thereof and benzoyl peroxide as described above, and placed inside the said compartment.
  • [0077]
    The container may be in any suitable form. It may especially be in the form of a bottle, a tube, a jar, a case, a can, a sachet or a box.
  • [0078]
    Preferably, the container comprises two compartments, and each of these compartments comprises either composition A or composition B.
  • [0079]
    The closing member may be in the form of a removable stopper, a lid, a cover, a tear-off strip or a cap, especially of the type comprising a body fixed to the container and a cap articulated on the body. It may also be in the form of a member ensuring the selective closure of the container, especially a pump, a valve or a clapper.
  • [0080]
    The closing member may be coupled to the container by screwing. Alternatively, the coupling from the closing member and the container may take place other than by screwing, especially via a bayonet mechanism, by click-fastening, gripping, welding, bonding or magnetic attraction. The term “click-fastening” in particular means any system involving the passing of a rim or bead of material by elastic deformation of a portion, especially of the closing member, followed by return to the elastically unstressed position of the said portion after the rim or bead has been passed.
  • [0081]
    The container may be at least partly made of thermoplastic material. Examples of thermoplastic materials include polypropylene and polyethylene.
  • [0082]
    Alternatively, the container is made of a non-thermoplastic material, especially of glass or metal (or alloy).
  • [0083]
    The container may have rigid walls or deformable walls, especially in the form of a tube or a tube bottle.
  • [0084]
    The container may comprise means for causing or facilitating the distribution of the composition. By way of example, the container may have deformable walls so as to make the composition come out in response to a positive pressure inside the container, this positive pressure being caused by elastic (or non-elastic) squeezing of the walls of the container. Alternatively, especially when the product is in the form of a stick, this stick may be driven by a piston mechanism. Still in the case of a stick, especially of makeup product, the container may comprise a mechanism, especially a wishbone mechanism, or a mechanism with a threaded stem, or with a helical ramp, which is capable of moving a stick in the direction of the said opening. Such a mechanism is described, for example, in FR 2,806,273 or in FR 2,775,566. Such a mechanism for a liquid product is described in FR 2,727,609.
  • [0085]
    In order to further illustrate the present invention and the advantages thereof, the following specific examples are given, it being understood that same are intended only as illustrative and in nowise limitative. In said examples to follow, all parts and percentages are given by weight, unless otherwise indicated.
  • EXAMPLES Example 1 Clinical Study Results
  • [0086]
    A clinical study for confirmation of efficacy was performed for a topical gel combining adapalene+benzoyl peroxide (BPO).
  • [0087]
    This gel has the following formulation (expressed as % weight/total weight):
  • [0000]
    Adapalene 0.10%
    Benzoyl peroxide 2.50%
    Copolymer of acrylamide & sodium 4.00%
    acryloyldimethyltaurate
    Sodium docusate 0.05%
    Disodium EDTA 0.10%
    Glycerol 4.00%
    Poloxamer 124 0.20%
    Propylene glycol 4.00%
    Purified water qs 100% 
  • Protocol
  • [0088]
    The clinical study was a multi-center, randomized, double-blind study in parallel groups, to evaluate the tolerance and the efficacy of the above formulation, in comparison with its own individual active substances placed at the same doses in gels of the same formula as that of the fixed combination (individual formulae referred to as “monads”) and in comparison with the gel vehicle (placebo formula): adapalene gel (0.1%), BPO gel (2.5%) and vehicle gel.
  • [0089]
    All the treatments were applied once a day for 12 weeks, to 517 patients suffering from acne.
  • [0090]
    The main efficacy criteria were:
  • [0091]
    the degree of success, defined as the percentage of patients considered as being “clear”, i.e., the patient has no more acne lesions (neither comedones nor inflammatory lesions), reflecting an improvement in the patient's clinical condition, or “almost clear” on the evaluation scale;
  • [0092]
    the reduction of the percentage of inflammatory and non-inflammatory lesions after 12 weeks of treatment.
  • Results
  • [0093]
    The results are presented in the Table that follows.
  • [0000]
    Efficacy in week 12 ITT*
    Adapalene Adapalene BPO
    0.1% + 0.1% 2.5% Vehicle
    BPO 2.5% alone alone (gel)
    N = 149 N = 148 N = 149 N = 71
    Degree of success 27.5% 15.5% 15.4% 9.9%
    (see FIG. 4)
    Progress of the
    lesions (median
    percentages)
    Number of −62.8% −45.7% −43.6% −37.8%
    inflammatory
    lesions
    (see FIG. 2)
    Number of non- −51.2% −33.3% −36.4% −37.5%
    inflammatory
    lesions
    (see FIG. 3)
    Total number of −51.0% −35.4% −35.6% −31.0%
    lesions
    (see FIG. 1)
    Progress of the
    lesions (as
    median absolute
    numbers)
    Number of −17 −13.0 −13.0 −11.0
    inflammatory
    lesions
    Number of non- −22.0 −17.0 −16.0 −14.0
    inflammatory
    lesions
    Total number of −40.0 −29.0 −27 −26.0
    lesions

    ITT* (analysis of intention to treat): all the patients randomized in a clinical test because they come under the indication selected for the treatment to be prescribed. The missing data are imputed by the last observation (LOCF method ** (Last Observation Carried Forward).
  • [0094]
    1) For the 4 main criteria of the study: degree of success and progress as a percentage of the three types of lesion, the fixed combination was found to be statistically superior to the two monads and to the vehicle.
  • [0095]
    2) When the effect of the gel used as vehicle (V) is subtracted from the effect of the fixed combination (C), the net clinical benefit of the fixed combination (C−V) is numerically superior to the sum of the net clinical benefits of each of the individual substances after subtraction of the vehicle effect from the adapalene (A) and BPO (B) branches, respectively, according to the equation:
  • [0000]

    (C−V)>(A−V)+(B−V).
  • [0096]
    These results systematically show a potentiation effect since the net benefit is in favor of the gel combining adapalene+BPO, with results, in terms of degree of success, that are superior to the addition of adapalene and BPO (28% for the combination, as opposed to 16%, 15% to 10% for adapalene, BPO and vehicle, respectively). In this case, the above equation shows (28−10)>(16−10)+(15−10), i.e., 18>11, which is true.
  • [0097]
    Similarly, the gel combining adapalene+BPO was numerically superior in terms of efficacy in comparison with the individual active substances and with the vehicle as regards the reduction in the number of all the lesions (reduction in the percentage of inflammatory and non-inflammatory lesions).
  • [0098]
    A potentiation effect of adapalene and BPO together is thus noted, since a 51% reduction in lesions is observed for the combination, as opposed to 35% for adapalene alone, 36% for BPO alone and 31% for the vehicle, which is expressed as a net benefit of efficacy with the above equation by (51−31)>(35−31)+(36−31), i.e., 20>9, which is true.
  • Example 2 Evaluation of the Anti-Inflammatory in Ear Oedema Model on Balb/c Mice
  • [0099]
    The study was carried out with 45 (5 par groups) female 9 weeks aged Balb/c ByJlc mice.
  • [0100]
    The Edema was induced by a single application of 20 μl of TPA dissolved in acetone at 0.01%.
  • [0101]
    The treatment was administrated by single topical application of tested compounds dissolved in TPA at 0.01% (groups 3,4,5,6 and 7) and dissolved in TPA 0.01%+BPO (groups 8, 9 and 10).
  • [0102]
    The treatments activity was measured by inflammation evaluation with ear thickness at T+6hours.
  • [0103]
    The results are presented in the following table and in FIG. 5.
  • [0000]
    Repeated Repeated
    Annova Testing Annova Testing
    Ear edema Inhibition vs TPA alone vs TPA + BPO
    Acetone Mean sem vs TPA (%) (Dose balanced) (Dose balanced)
    TPA 0.01% 26.80 3.35
    TPA 0.01 + CD153 0.01% 2.20 0.37 91.8 0.042
    (controle)
    TPA 0.01% + BPO at 2.5% 22.40 2.23 16.4
    TPA 0.01% + BPO at 5% 20.40 2.62 23.9
    TPA 0.01% + BPO at 10% 16.20 4.03 39.6
    TPA 0.01% + Adapalene at 0.1% 23.40 2.01 12.7 0.0015
    TPA 0.01% + Adapalene at 0.1% + 14.00 2.51 47.8
    BPO at 2.5%
    TPA 0.01% + Adapalene at 0.1% + 10.00 2.26 62.7
    BPO at 5%
    TPA 0.01% + Adapalene at 0.1% + 11.00 3.03 59.0
    BPO at 10%
  • Conclusion
  • [0104]
    After a single topical application of the positive control CD0153 (0.01%) diluted in TPA solution, we observed a decrease of 92% of the ear thickness.
  • [0105]
    BPO at 2.5%, 5% and 10% has a slight anti-inflammatory effect, reducing the TPA-induced ear edema respectively by 16%, 24% and 40%, with a statistically significant dose balanced effect (0.042).
  • [0106]
    Adapalene alone has a low anti-inflammatory effect, reducing the TPA-induced ear edema by 13%.
  • [0107]
    Variation of concentration of BPO was measured in combination with adapalene. Therefore, combinations of BPO at 2.5%, 5% and 10% with Adapalene at 0.1% reduce the TPA-induced ear edema respectively by 48%, 63% and 59%. Combination treatment is statistically more efficient than BPO alone (0.0015) even though the dose effect of the latest group is non-significant regarding the TPA alone group (0.1089).
  • [0108]
    Adapalene at 0.1% increases the anti-inflammatory effect obtained with BPO whatever the tested doses.
  • [0109]
    Lower doses of BPO will be used to attempt to show a dose related effect for the association.
  • [0110]
    These results show a potential synergistic anti-inflammatory effect of the combination compared to the compounds singly applied.
  • [0111]
    Each patent, patent application, publication, text and literature article/report cited or indicated herein is hereby expressly incorporated by reference in its entirety.
  • [0112]
    While the invention has been described in terms of various specific and preferred embodiments, the skilled artisan will appreciate that various modifications, substitutions, omissions, and changes may be made without departing from the spirit thereof. Accordingly, it is intended that the scope of the present invention be limited solely by the scope of the following claims, including equivalents thereof.

Claims (22)

    What is claimed is:
  1. 1. A method for reducing the number of acne lesions, comprising administering to an individual afflicted therewith, a thus effective amount of a pharmaceutical composition which comprises adapalene or a pharmaceutically acceptable salt thereof, administered in combination or in a concomitant application with benzoyl peroxide.
  2. 2. The method as defined by claim 1, comprising administering a pharmaceutical composition which comprises fixed combination which comprises (i) at least one compound selected from among adapalene and pharmaceutically acceptable salts thereof, and (ii) benzoyl peroxide, formulated into a pharmaceutically acceptable medium therefor.
  3. 3. The method as defined by claim 1, said acne lesions being of inflammatory and/or non-inflammatory type.
  4. 4. The method as defined by claim 3, in which the reduction of the number of inflammatory and/or non-inflammatory acne lesions is at least about 40%.
  5. 5. The method as defined by claim 2, comprising administering a pharmaceutical composition in which the adapalene and the benzoyl peroxide are present in synergistic amounts. 25
  6. 6. The method as defined by claim 2, wherein the pharmaceutical composition comprises 0.1% of adapalene and 2.5% of benzoyl peroxide.
  7. 7. The method as defined by claim 2, wherein the pharmaceutical composition is a gel.
  8. 8. The method as defined by claim 1, wherein the pharmaceutical composition is adapted for topical application.
  9. 9. The method as defined by claim 1, wherein the pharmaceutical composition is in the form of a composition A comprising adapalene, to be applied concomitantly with a composition B comprising benzoyl peroxide.
  10. 10. The method as defined by claim 9, wherein the adapalene and the benzoyl peroxide are present, respectively, in compositions A and B in synergistic amounts.
  11. 11. The method as defined by claim 9, wherein composition A comprises 0.1% of adapalene and composition B comprises 2.5% of benzoyl peroxide.
  12. 12. The method as defined by claim 9, wherein the compositions A and B are gels.
  13. 13. The method as defined by claim 9, wherein the composition A and composition B are presented in the form of a kit.
  14. 14. The method as defined by claim 13, wherein the kit comprises two isolated compartments each containing one of the two pharmaceutical compositions A or B.
  15. 15. The method as defined by claim 13, wherein the kit comprises at least one association of the two compositions A and B, in two separate packages in the same presentation.
  16. 16. The method as defined by claim 9, wherein the said pharmaceutical composition is composition A, to be applied in any order or sequentially, within a time interval of less than 1 hour, with composition B.
  17. 17. The method as defined by claim 9, wherein the compositions A and B are adapted for topical application.
  18. 18. The method as defined by claim 3, wherein the pharmaceutical composition is useful for reducing the number of inflammatory acne lesions.
  19. 19. The method as defined by claim 3, wherein the pharmaceutical composition is useful for reducing the number of non-inflammatory acne lesions.
  20. 20. A method for potentiating the action of benzoyl peroxide, comprising administering therewith adapalene or a pharmaceutically acceptable salt thereof.
  21. 21. A kit comprising at least two components:
    a first component which comprises at least adapalene or a pharmaceutically acceptable salt thereof, and
    a second component which comprises benzoyl peroxide.
  22. 22. A product comprising:
    (i) a container delimiting at least one compartment, the said container being sealed by means of a closing member; and
    (ii) a pharmaceutical composition which comprises adapalene or a pharmaceutically acceptable salt thereof and benzoyl peroxide, confined inside the said compartment.
US13296186 2006-07-13 2011-11-14 Combinations of adapalene and benzoyl peroxide for treating acne lesions Pending US20120059063A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR0652968 2006-07-13
FR0652968A FR2903603B1 (en) 2006-07-13 2006-07-13 adapalene combination and benzol peroxide in the treatment of acne
US83349106 true 2006-07-27 2006-07-27
PCT/EP2007/057207 WO2008006888A1 (en) 2006-07-13 2007-07-12 Combination of adapalene and benzoyl peroxide for treating acne lesions
US12318937 US8071644B2 (en) 2006-07-13 2009-01-13 Combinations of adapalene and benzoyl peroxide for treating acne lesions
US13296186 US20120059063A1 (en) 2006-07-13 2011-11-14 Combinations of adapalene and benzoyl peroxide for treating acne lesions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13296186 US20120059063A1 (en) 2006-07-13 2011-11-14 Combinations of adapalene and benzoyl peroxide for treating acne lesions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US12318937 Continuation US8071644B2 (en) 2006-07-13 2009-01-13 Combinations of adapalene and benzoyl peroxide for treating acne lesions

Publications (1)

Publication Number Publication Date
US20120059063A1 true true US20120059063A1 (en) 2012-03-08

Family

ID=37763873

Family Applications (6)

Application Number Title Priority Date Filing Date
US11826364 Active 2029-01-11 US8129362B2 (en) 2006-07-13 2007-07-13 Combination/association of adapalene and benzoyl peroxide for treating acne lesions
US12318937 Active 2027-09-04 US8071644B2 (en) 2006-07-13 2009-01-13 Combinations of adapalene and benzoyl peroxide for treating acne lesions
US13296186 Pending US20120059063A1 (en) 2006-07-13 2011-11-14 Combinations of adapalene and benzoyl peroxide for treating acne lesions
US13351986 Active US8785420B2 (en) 2006-07-13 2012-01-17 Combination/association of adapalene and benzoyl peroxide for treating acne lesions
US14301816 Pending US20140296340A1 (en) 2006-07-13 2014-06-11 Combination/association of adapalene and benxoyl peroxide for treating acne lesions
US15476241 Pending US20170202803A1 (en) 2006-07-13 2017-03-31 Combination/association of adapalene and benzoyl peroxide for treating acne

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US11826364 Active 2029-01-11 US8129362B2 (en) 2006-07-13 2007-07-13 Combination/association of adapalene and benzoyl peroxide for treating acne lesions
US12318937 Active 2027-09-04 US8071644B2 (en) 2006-07-13 2009-01-13 Combinations of adapalene and benzoyl peroxide for treating acne lesions

Family Applications After (3)

Application Number Title Priority Date Filing Date
US13351986 Active US8785420B2 (en) 2006-07-13 2012-01-17 Combination/association of adapalene and benzoyl peroxide for treating acne lesions
US14301816 Pending US20140296340A1 (en) 2006-07-13 2014-06-11 Combination/association of adapalene and benxoyl peroxide for treating acne lesions
US15476241 Pending US20170202803A1 (en) 2006-07-13 2017-03-31 Combination/association of adapalene and benzoyl peroxide for treating acne

Country Status (11)

Country Link
US (6) US8129362B2 (en)
EP (2) EP2450035A1 (en)
JP (3) JP2009542779A (en)
KR (3) KR20150003917A (en)
CN (1) CN101541320B (en)
CA (1) CA2656456A1 (en)
DK (1) DK2046318T3 (en)
ES (1) ES2423951T3 (en)
FR (1) FR2903603B1 (en)
RU (3) RU2009104949A (en)
WO (1) WO2008006888A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080176954A1 (en) * 2001-12-21 2008-07-24 Galderma Research & Development, S.N.C. Dermatological/cosmetic gels comprising at least one retinoid and benzoyl peroxide

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2910320B1 (en) * 2006-12-21 2009-02-13 Galderma Res & Dev S N C Snc Emulsion comprising at least one retinoid and benzole peroxide
EP2114392B1 (en) 2007-01-30 2015-06-10 Galderma Research & Development Use of adapalene and benzoyl peroxide for the long term treatment of acne vulgaris
JP5622582B2 (en) * 2007-11-30 2014-11-12 ガルデルマ・リサーチ・アンド・デヴェロップメント At least one naphthoic acid derivatives, compositions comprising benzoyl peroxide and at least one film-forming agent, methods for their preparation, and use thereof
EP2288349A1 (en) * 2008-05-16 2011-03-02 Galderma Research & Development Therapy regimen for treating acne related diseases
KR20120118064A (en) * 2010-02-09 2012-10-25 갈데르마 리써어치 앤드 디벨로프먼트 A dermatological composition comprising a combination of adapalene and benzoyl peroxide for the treatment of acne in non-caucasian population with decrease of post-inflammatory hyperpigmentation
WO2011135090A1 (en) * 2010-04-29 2011-11-03 Galderma Research & Development Method for treating scars with adapalene 0.3%
FR2969491B1 (en) * 2010-12-23 2013-07-12 Galderma Res & Dev dermatological foams obtained from a gel or a suspension containing a combination of adapalene and BPO
US8563535B2 (en) * 2011-03-29 2013-10-22 Kamal Mehta Combination composition comprising benzoyl peroxide and adapalene
WO2013175011A1 (en) * 2012-05-25 2013-11-28 Galderma Research & Development Treatment of preadolescent moderate acne vulgaris
JP6285946B2 (en) * 2012-11-20 2018-02-28 アラーガン、インコーポレイテッドAllergan,Incorporated Topical dapsone and dapsone / adapalene compositions and methods of use thereof
KR20160130862A (en) * 2014-04-01 2016-11-14 갈데르마 리써어치 앤드 디벨로프먼트 Combination of adapalene and benzoyl peroxide for treating acne scars
WO2016012352A1 (en) 2014-07-25 2016-01-28 Galderma Research & Development Combination of adapalene and benzoyl peroxide for the treatment of severe acne

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170196A1 (en) * 2001-12-21 2003-09-11 Sandrine Orsoni Dermatological/cosmetic gels comprising at least one retinoid and benzoyl peroxide
US20040157766A1 (en) * 2003-01-23 2004-08-12 Edko Trading And Representation Co. Ltd. Topical pharmaceutical and/or cosmetic dispense systems
US20070003585A1 (en) * 2005-06-29 2007-01-04 Stiefel Laboratories, Inc. Topical skin treating compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07504168A (en) * 1992-02-18 1995-05-11
FR2727609B1 (en) 1994-12-06 1997-01-10 Oreal A dispensing assembly for applying a liquid product pasty consistency
FR2775566B1 (en) 1998-03-03 2000-05-12 Oreal Stick-carrying cup and packaging assembly for a makeup product having the
US6559189B2 (en) * 1999-04-28 2003-05-06 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
FR2806273B1 (en) 2000-03-16 2002-10-04 Oreal packaging and applicator device of a cosmetic or care product
FR2833841B1 (en) * 2001-12-21 2005-07-22 Galderma Res & Dev Gel comprising at least one retinoid and benzoyl peroxide
FR2837101B1 (en) 2002-03-12 2004-07-02 Galderma Res & Dev Use of 6- [1-adamantyl) -4-methoxyphenyl] -2-naphthoic for the treatment of dermatological disorders
JP2006528645A (en) * 2003-07-23 2006-12-21 ゾーマ テクノロジー リミテッド For the treatment of acne, use of xmp-629
US20050239723A1 (en) * 2004-04-27 2005-10-27 Amin Avinash N Compositions and methods useful for treatment of acne
US20060128808A1 (en) * 2004-10-20 2006-06-15 Galderma Research & Development, S.N.C. Method of using adapalene in acne maintenance therapy
FR2901139B1 (en) * 2006-05-17 2009-03-20 Galderma Res & Dev S N C Snc Compositions comprising at least one naphthoic acid and benzoyl peroxide, their processes of preparation, and their uses

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170196A1 (en) * 2001-12-21 2003-09-11 Sandrine Orsoni Dermatological/cosmetic gels comprising at least one retinoid and benzoyl peroxide
US7820186B2 (en) * 2001-12-21 2010-10-26 Galderma Research & Development Gel composition for once-daily treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt
US8105618B2 (en) * 2001-12-21 2012-01-31 Galderma Research & Development Dermatological/cosmetic gels comprising at least one retinoid and/or retinoid salt and benzoyl peroxide
US8241649B2 (en) * 2001-12-21 2012-08-14 Galderma Research & Development Dermatological/cosmetic gels comprising at least one retinoid and/or retinoid salt and benzoyl peroxide
US20040157766A1 (en) * 2003-01-23 2004-08-12 Edko Trading And Representation Co. Ltd. Topical pharmaceutical and/or cosmetic dispense systems
US20070003585A1 (en) * 2005-06-29 2007-01-04 Stiefel Laboratories, Inc. Topical skin treating compositions

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080176954A1 (en) * 2001-12-21 2008-07-24 Galderma Research & Development, S.N.C. Dermatological/cosmetic gels comprising at least one retinoid and benzoyl peroxide
US8241649B2 (en) 2001-12-21 2012-08-14 Galderma Research & Development Dermatological/cosmetic gels comprising at least one retinoid and/or retinoid salt and benzoyl peroxide
US8936800B2 (en) 2001-12-21 2015-01-20 Galderma Research & Development Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt
US9814690B2 (en) 2001-12-21 2017-11-14 Galderma Research & Development Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt

Also Published As

Publication number Publication date Type
ES2423951T3 (en) 2013-09-25 grant
CN101541320B (en) 2014-04-09 grant
WO2008006888A1 (en) 2008-01-17 application
US8129362B2 (en) 2012-03-06 grant
JP2014040481A (en) 2014-03-06 application
US20090253788A1 (en) 2009-10-08 application
FR2903603B1 (en) 2009-03-20 grant
US8785420B2 (en) 2014-07-22 grant
RU2009104949A (en) 2010-08-20 application
RU2012136952A (en) 2014-03-10 application
KR20150003917A (en) 2015-01-09 application
FR2903603A1 (en) 2008-01-18 application
JP2016029094A (en) 2016-03-03 application
KR20090028764A (en) 2009-03-19 application
US20080033047A1 (en) 2008-02-07 application
US20170202803A1 (en) 2017-07-20 application
RU2012144414A (en) 2014-04-27 application
CN101541320A (en) 2009-09-23 application
JP2009542779A (en) 2009-12-03 application
US8071644B2 (en) 2011-12-06 grant
EP2450035A1 (en) 2012-05-09 application
DK2046318T3 (en) 2013-08-05 grant
EP2046318A1 (en) 2009-04-15 application
KR20160120352A (en) 2016-10-17 application
US20120115947A1 (en) 2012-05-10 application
US20140296340A1 (en) 2014-10-02 application
CA2656456A1 (en) 2008-01-17 application
EP2046318B1 (en) 2013-06-05 grant

Similar Documents

Publication Publication Date Title
Pelle et al. Rosacea: II. therapy
US4247547A (en) Tretinoin in a gel vehicle for acne treatment
US7083799B1 (en) No-synthase inhibitors
US7252816B1 (en) Topical acne vulgairs medication with a sunscreen
US5990100A (en) Composition and method for treatment of psoriasis
US5690923A (en) Stable topical retinoid compositions
US8618081B2 (en) Compositions, gels and foams with rheology modulators and uses thereof
US5643584A (en) Aqueous gel retinoid dosage form
US6955816B2 (en) Anti-aging skin care composition and uses thereof
US7141237B2 (en) Pharmaceutical foam
US6649176B1 (en) Compositions containing mineral water
US20010002396A1 (en) Compositions and methods of treating skin conditions
US20020039591A1 (en) Topical applications for skin treatment
Krautheim et al. Acne: topical treatment
US20040156873A1 (en) Topically Bioavailable Acne and Rosacea Treatment Compositions
US5252604A (en) Compositions of retinoic acids and tocopherol for prevention of dermatitis
US6387383B1 (en) Topical low-viscosity gel composition
US5466446A (en) Topical compositions containing bensoyl peroxide and clindamycin and method of use thereof
Cunliffe et al. Is combined oral and topical therapy better than oral therapy alone in patients with moderate to moderately severe acne vulgaris? A comparison of the efficacy and safety of lymecycline plus adapalene gel 0.1%, versus lymecycline plus gel vehicle 1
US20050239894A1 (en) Topical composition
US20060147383A1 (en) Sprayable compositions comprising pharmaceutical active agents, volatile silicones and a non-volatile oily phase
US20030170187A1 (en) Skin treatments containing nano-sized vitamin K
WO1997015282A1 (en) Compositions for the treatment of dermatological disorders and methods for their use
US20060269504A1 (en) Use of alkyl resorcinols in the treatment of acne
US20030004118A1 (en) Antibiotic/benzoyl peroxide dispenser